Literature DB >> 30859277

[Orphan drugs].

Jürgen R Schäfer1, Claus F Vogelmeier2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30859277     DOI： 10.1007/s00108-019-0582-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  8 in total

1.  The mystery of PCSK9.

Authors:  Alan D Attie
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08       Impact factor: 8.311

Review 2.  [Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges].

Authors:  Wolf-Dieter Ludwig
Journal:  Internist (Berl)       Date:  2019-04       Impact factor: 0.743

Review 3.  [Orphan drugs from the perspective of research-based pharmaceutical and biotech companies].

Authors:  Sabine Sydow; Siegfried Throm
Journal:  Internist (Berl)       Date:  2019-04       Impact factor: 0.743

4.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

Review 5.  [Orphan drugs : New opportunities for the treatment of rare diseases].

Authors:  M Beck
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

6.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

7.  Targeting PCSK9 for the treatment of hypercholesterolemia.

Authors:  Joseph A Hedrick
Journal:  Curr Opin Investig Drugs       Date:  2009-09

8.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.